

Corporate Presentation References

Armand, P., et al., *Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation*. Blood, 2014. **123**(23): p. 3664-71. ([PDF](#))

Besse, K.L., et al., *Estimating demand and unmet need for allogeneic hematopoietic cell transplantation in the United States using geographic information systems*. J Oncol Pract, 2015. **11**(2): p. e120-30 ([PDF](#))

Boenig, Halvard B. et al., *Add back of selectively depleted alloreactive T-cells retaining the full immune repertoire of mature T-cells improves event-free survival (GRFS) and overall survival in a T-cell depleted haploidentical HSCT*. Cytotherapy 2017. 19(5), e2 - e3 ([PDF](#))

Broder, M.S., et al., *The Cost of Hematopoietic Stem-Cell Transplantation in the United States*. Am Health Drug Benefits, 2017. 10(7): p. 366-374. ([PDF](#))

CHMP Assessment Report 2017 ([PDF](#))

CIBMTR 2017 Summary Slides ([website](#))

Ciurea, S.O., et al., *Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation*. Biol.Blood Marrow Transplant., 2012. **18**(12): p. 1835-1844 ([PDF](#))

Ciurea, S.O., et al., *Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia*. Blood, 2015. **126**(8): p. 1033-1040 ([PDF](#))

Devillier, R., et al., *T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes*. Bone Marrow Transplant, 2016. **51**(2): p. 194-8 ([PDF](#))


Di Stasi, A., et al., *Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors*. Biol.Blood Marrow Transplant, 2014. **20**(12): p. 1975-1981 ([PDF](#))

Esquirol A., et al., *Haploidentical T-cell replete hematopoietic transplantation conditioned with thiotepa-busulfan-fludarabine (TBF) followed by high-dose cyclophosphamide and tacrolimus as graft versus host disease prophylaxis in 33 patients with myeloid disease*. Bone Marrow Transplantation, 2016. **51**, p. S314–S513

Fuchs, E.J., *Related haploidentical donors are a better choice than matched unrelated donors: Point*. Blood Advances, 2017. **1**(6): p. 397-400 ([PDF](#))

Gragert, L., et al., *HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry*. N Engl J Med, 2014. **371**(4): p. 339-48 ([PDF](#))

Jones, C., et al., *Estimating the Burden of Cost in Chronic Graft-versus-Host Disease: A Human Capital Approach*. Journal of Health Economics and Outcomes Research, 2016. **4**(2): p. 6 ([PDF](#))



Corporate Presentation References

Khera, N., et al., *Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens*. *Oncologist*, 2014. **19**(6): p. 639-44. ([PDF](#))

Koreth, J., et al., *Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis*. *J Clin Oncol*, 2013. **31**(21): p. 2662-70. ([PDF](#))

Lewalle, P., et al., *Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study*. *Bone Marrow Transplant.*, 2003. **31**(1): p. 39-44. ([PDF](#))

Locatelli, F., et al., *Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion*. *Blood*, 2017. ([PDF](#))

Mariotto, A.B., et al., *Projections of the cost of cancer care in the United States: 2010-2020*. *J Natl Cancer Inst*, 2011. **103**(2): p. 4515-23. ([PDF](#))

McCurdy, S.R., et al., *Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide*. *Haematologica*, 2017. **102**(2): p. 391-400 ([PDF](#))

Merli, P., et al., *Impact of post-transplant infusion of donor T cells genetically modified with inducible caspase 9 suicide gene (BPX-501 cells) on children with leukemia given alpha-beta T-cell depleted HAPLO-HSCT*. EHA Learning Center, 2017; 181782 ([Abstract](#))

Milliman Research Report 2017 U.S. organ and tissue transplant cost estimates and discussion. 2017. ([PDF](#))


Mrózek K., et al., *Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia*. *J Clin Oncol*, 2012. **30**(36): p. 2662-70. ([PDF](#))

Passweg, J.R., et al., *Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report*. *Bone Marrow Transplant*, 2018. ([PDF](#))

Piemontese, S., et al., *A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia*. *J Hematol Oncol*, 2017. **10**(1): p. 24 ([PDF](#))

Solh, M., et al., *Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center*. *Biol Blood Marrow Transplant*, 2016. **22**(8): p. 1403-9 ([Abstract](#))

Solh, M., et al., *Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint*. *Biol Blood Marrow Transplant*, 2017. **23**(12): p. 2192-2198. ([Abstract](#))



Corporate Presentation References

Solomon, S.R., et al., *Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial*. *Biol.Blood Marrow Transplant.*, 2012. **18**(12): p. 1859-1866 ([PDF](#))

Sugita, J., et al., *HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning*. *Biol.Blood Marrow Transplant*, 2015. **21**(9): p. 1646-1652 ([PDF](#))

Yu, J., et al., *Influence of acute graft-versus-host disease (aGVHD) during allogeneic hematopoietic stem cell transplantation (HSCT) engraftment admission on hospital length of stay (LOS), charges, and costs*. *Journal of Clinical Oncology*, 2017. **35**(15_suppl): p. e18544-e18544. ([Abstract](#))